ÂÜÀòÂÒÂ×

Kirsten Flowers is currently the Chief Commercial Officer for Kura Oncology and brings more than 15 years of pharmaceutical and biotech experience successfully leading commercial and product planning activities. Kirsten has previously served as SVP of Commercial Operations at Array Biopharma where she built and led the commercial organization that delivered the successful launch of Braftovi® + Mektovi® for patients with BRAF-mutant melanoma. Before joining Array, she held several leadership positions within Pfizer including the U.S. commercial lead for the launch of the blockbuster drugs IBRANCE® in breast cancer and INLYTA® in renal cell carcinoma. Kirsten earned her MBA from Harvard Business School, and her BS in Molecular & Cellular Biology and Psychology from the University of Arizona.